PACTR202211709374727尚未招募2 期
A Randomized, Double-Blind, Placebo Controlled Phase 2 Study to assess the safety and efficacy of a combination of Tadalafil, Silodosin and Paroxetine HCI CR use concurrently for Premature Ejaculation (PE)
zyvran pharmaceuticals0 个研究点目标入组 60 人开始时间: 2022年11月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Male
入选标准
- •1)Ages 18-49 (include 18 and 49) years old male
- •2)Have sexual intercourse with female on a regular basis (at least twice a week)
- •3)Intra-vaginal Latency Time (IVLT) < 1 min consistently for at least one year
排除标准
- •1)Use of Certain medications/agents (e.g., Nitrates, other antihypertensive, grapefruit juice)
- •2)Known hypersensitivity to study agents
- •3)Current or history of kidney disease. GFR< 50
- •4)Recent History of MI
- •5)History of Erectile dysfunction
研究者
相似试验
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyMedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2016-003900-30-IEAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAcute Myeloid LeukemiaEUCTR2016-003900-30-GBAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAcute Myeloid LeukemiaEUCTR2016-003900-30-CZAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAcute Myeloid LeukemiaEUCTR2016-003900-30-DEAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyMedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2016-003900-30-BEAbbVie Deutschland GmbH & Co. KG210